Login / Signup

Efficacy of Switching to Adalimumab for Maintenance of Remission Following Induction Therapy with Tacrolimus in Patients with Ulcerative Colitis.

Keijiro NumaKazuki KakimotoYasuyoshi TanakaNoboru MizutaNaohiko KinoshitaKei NakazawaRyoji KoshibaYuki HirataKazuhiro OtaTakako MiyazakiShiro NakamuraKazuhide HiguchiHiroki Nishikawa
Published in: Journal of clinical medicine (2023)
switching to ADA for remission maintenance in patients with refractory UC who achieved clinical remission with TAC is clinically useful.
Keyphrases
  • ulcerative colitis
  • disease activity
  • rheumatoid arthritis
  • stem cells
  • juvenile idiopathic arthritis